Please Wait
Applying Filters...
menu
    • menu
    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Pegloticase

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA
    Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA

    06 Jul 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230706657904/en

    BUSINESSWIRE
    06 Jul 2023
    Share Share
    Amgen dives deeper into rare disease drugs with $27.8 bln Horizon deal
    Amgen dives deeper into rare disease drugs with $27.8 bln Horizon deal

    13 Dec 2022

    // REUTERS

    https://www.reuters.com/markets/deals/amgen-set-buy-biotech-firm-horizon-26-bln-valuation-bloomberg-news-2022-12-12/?rpc=401&

    REUTERS
    13 Dec 2022
    Share Share
    Sustained Patient Response to KRYSTEXXA® (pegloticase) Inj with Methotrexate
    Sustained Patient Response to KRYSTEXXA® (pegloticase) Inj with Methotrexate

    08 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221108005040/en

    BUSINESSWIRE
    08 Nov 2022
    Share Share
    Data Support the Use of KRYSTEXXA with Methotrexate to Treat Uncontrolled Gout
    Data Support the Use of KRYSTEXXA with Methotrexate to Treat Uncontrolled Gout

    05 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221105005026/en

    BUSINESSWIRE
    05 Nov 2022
    Share Share
    Krystexxa plus methotrexate approved for uncontrolled gout
    Krystexxa plus methotrexate approved for uncontrolled gout

    09 Jul 2022

    // Zoey Becker FIERCEPHARMA

    https://www.fiercepharma.com/pharma/horizons-krystexxa-gets-new-combo-indication-methotrexate-breathes-new-life-drug

    Zoey Becker FIERCEPHARMA
    09 Jul 2022
    Share Share
    Horizon Pharma Pegloticase Receives Supplemental Approval in US
    Horizon Pharma Pegloticase Receives Supplemental Approval in US

    07 Jul 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125293

    FDA
    07 Jul 2022
    Share Share